HANNOVER, Germany and SAN DIEGO, USA, October 24th, 2023 — Implandata Ophthalmic Products, an emerging ophthalmic health tech company based in Germany and USA, announced that Dr. Adrienne Graves and Mr. Jan Willem de Cler are appointed as new members of the company’s Board of Directors. Jan Willem de Cler will also take over responsibility as Chairman of the Board.
HANNOVER, Germany, Oct. 24, 2023 /PRNewswire-PRWeb/ — A visual scientist by training and a global industry leader in ophthalmology, Dr. Adrienne Graves brings extensive experience to Implandata. As the former CEO of Santen Inc., she successfully established a strong global presence, bringing multiple ophthalmic products through development to approval and commercialization and leading global teams through successful acquisitions and partnerships. Prior to Santen, she spent 9 years at Alcon, joining as Senior Scientist to establish Alcon’s first Retinal Electrophysiology Laboratory. She progressed through roles of increasing responsibility in research and development, including directing clinical development in multiple therapeutic areas and serving as Director of International Ophthalmology. Dr. Graves currently serves as a director on the boards of various ophthalmic pharmaceutical and health-tech companies. She serves on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, Foundation Fighting Blindness (FFB) and the RD (Retinal Degeneration) Fund. Dr. Graves also co-founded Glaucoma 360 and OWL (Ophthalmic World Leaders, formerly Ophthalmic Women Leaders).
Jan Willem de Cler, was Member of the DAX listed Carl Zeiss Meditec AG Management Board until September 2022, after which he became Executive in Residence and Senior Advisor to Private Equity and Non-Executive Director. Jan Willem studied Business Administration at Nijenrode University in the Netherlands and the University of Oregon, USA where he accomplished his MBA. Jan Willem then started his career at General Electric’s FMP and Corporate Audit Staff and spent the next 25 years in Health Care. He held different management positions at GE Medical Systems and became co-founder and Head of Sales and Marketing for GHX – Global Healthcare Exchange Europe, a successful startup that provides B2B solutions for supply chain efficiency between healthcare providers and suppliers. Jan Willem joined ZEISS Group in 2004 as Managing Director for the Benelux, and the French sales and service companies for all divisions, as well as serving as the President of France Chirurgie Instrumentation (FCI). From 2010 he led the Surgical Ophthalmology SBU at Carl Zeiss Meditec AG and built it up to its global leadership position. In 2018 he was appointed to the Board of Carl Zeiss Meditec AG as COO/CHRO/CSO and led M&A.
Implandata Ophthalmic Products, is an ophthalmic health-tech company dedicated to improving the lives of millions of people with glaucoma. Breakthroughs in bio-sensing, telemetry and data analytics led to the EYEMATE system. The CE-marked EYEMATE system is in use at leading eye centers in Europe. In the US market, EYEMATE has obtained the FDA “Breakthrough Device Designation” and IDE studies are in preparation.
Media Contact
Max Ostermeier, Implandata Ophthalmic Products, 49 51122042581, [email protected], https://www.implandata.com/
SOURCE Implandata Ophthalmic Products
